With 8.4% CAGR, Immunohistochemistry (IHC) Market to Worth USD 3.9 billion by 2030, Growth Rate, Size, Shares, Trends, Demands, Revenue Analysis

According to the study titled, "Immunohistochemistry (IHC) Market by Product (Antibodies, Reagents, Equipment, Kits), Application (Diagnostics (Cancer, Infectious, Autoimmune Diseases), Research, Forensic), End user (Hospitals, Diangostic labs, Academia), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa and South America)" launched by Delvens, The Global Immunohistochemistry (IHC) Market is projected to reach USD 3.9 billion by 2030 at a CAGR of 8.4% during the forecast period of 2023 to 2030.

Immunohistochemistry (IHC) Market research report contains the company profiles, product specifications, capacity, production value, and market shares of each company for the forecasted period of 2023-2030. The report also studies company profiles with respect to company snapshot, geographical presence, product portfolio, and recent developments. Businesses can successfully utilize the data, statistics, research, and insights about the Immunohistochemistry (IHC) industry included in this marketing report to make decisions about business strategies and to achieve maximum return on investment (ROI). Immunohistochemistry (IHC) Market research report helps to provide such market insights by considering all the aspects of current and future market.

To Understand Business Strategies, Request For a Sample Report at: https://www.delvens.com/get-free-sample/immunohistochemistry-market-trends-forecast-till-2028

The use of antibodies to visualize the distribution and localization of certain proteins in tissues is known as immunohistochemistry (IHC). Understanding the molecular mechanisms behind illness requires the ability to recognize and analyze protein expression in cells and tissues, which is made possible by this approach.

A tissue sample is first fixed and paraffin wax-embedded for IHC. After endogenous peroxidase activity has been inhibited, thin tissue slices are placed on slides. The primary antibody that selectively binds to the target protein is next treated with the tissue sections. A secondary antibody that has been coupled to an enzyme, such as horseradish peroxidase (HRP), that recognizes and binds to the primary antibody is then added next.

The enzyme then combines with a chromogenic substrate to create a visible signal that may be seen under a microscope. The color and strength of the signal reveal the presence and concentration of the desired protein in the tissue.

IHC is often used to examine protein expression and localization in a range of tissues, including tumor samples, in both research and clinical settings. Additionally, by examining changes in protein expression, it may be used to distinguish between different cell types in a tissue sample and assess the efficacy of various therapies.

Immunohistochemistry (IHC) Market Key Players:

F. Hoffman-La Roche AG
Danaher Corporation
Agilent Technologies, Inc.
Merck KGaA
Bio-Rad Laboratories, Inc.
Bio-Techne Corporation
Abcam plc
Becton, Dickinson and Company
PerkinElmer, Inc.
Takara Bio, Inc.
Thermo Fisher Scientific, Inc.
PHC Holdings Corporation
Cell Signaling Technology, Inc.
Bio SB, Inc.
Miltenyi Biotec
CANDOR Bioscience GmbH
Sakura Finetek Japan Co., Ltd.
Eagle Biosciences, Inc.
Biocare Medical, LLC
Elabscience, Inc.
Biogenex Laboratories
Diagnostic Biosystems, Inc.
BioVision Inc.
Rockland Immunochemicals, Inc.
Genemed Biotechnologies, Inc.

MAJOR DEVELOPMENTS IN THE MARKET

Roche Diagnostics: For patients with non-small cell lung cancer (NSCLC), Roche Diagnostics has introduced a novel IHC test for assessing the expression of programmed cell death ligand-1 (PD-L1). The VENTANA BenchMark ULTRA automated staining device is intended for use with the test, known as VENTANA PD-L1 (SP142) test.

Agilent Technologies: The Ultivue InSituPD-L1 test, a novel IHC platform from Agilent Technologies, was unveiled. The assay's excellent sensitivity and specificity make it possible to identify PD-L1 expression in tumor samples.

Danaher Corporation: The Bioprocess business unit of Cytiva, which offers goods and services for IHC as well as other applications in the production of biopharmaceuticals and the life sciences, has been acquired, according to an announcement from Danaher Corporation.

Thermo Fisher Scientific: The Invitrogen TrueVIEW Autofluorescence Quenching Kit, a new IHC platform from Thermo Fisher Scientific, is now available. The kit is intended to get rid of tissue samples' autofluorescence, which can get in the way of IHC staining and analysis.

Merck KGaA: The ONCOQUEST Dx Target System, a novel IHC platform, was introduced by Merck KGaA. The method is intended to make it possible to identify several targets in a single tissue sample, which can give more detailed information about tumor biology and direct treatment choices.

"These advances are a result of continuing work by major IHC market participants to create new products and technologies that can increase the precision and effectiveness of tissue protein detection and analysis."

Grow Your Business Revenue Make an Inquiry Before Buying at: https://www.delvens.com/Inquire-before-buying/immunohistochemistry-market-trends-forecast-till-2028

MARKET ANALYSIS BASED ON SEGMENTATION

Product

The product category comprises software, tools, kits, reagents, and antibodies. The market leader and largest product segment, antibodies, are anticipated to maintain their dominance. Due to the rising requirement for standardized procedures and ready-to-use reagents, the kits market is also expanding significantly.

Application

The application sector covers a variety of topics, including medication development, infectious illness detection, and cancer research. The largest application category, which focuses on cancer diagnosis and research, is anticipated to keep expanding as a result of rising cancer incidence rates and the demand for personalized therapy.

End-User

Hospitals, diagnostic centers, study facilities, and pharmaceutical and biotechnology firms make up the end-user segment. The biggest end-user sector, hospitals, and diagnostic labs, is anticipated to keep expanding as a result of the rising demand for diagnostic tests and the expanding number of hospital and clinical laboratories.

Region

North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa are all included in the region category. The biggest market for IHC right now is North America, followed by Europe and Asia-Pacific. Due to the rising demand for personalized medication and increased expenditures in healthcare infrastructure, the Asia-Pacific region is anticipated to develop at the quickest rate in the upcoming years.

"In the upcoming years, the immunohistochemistry (IHC) market is anticipated to expand significantly due to factors such as the rising prevalence of cancer and other illnesses, the rising desire for personalized medication, and technological advancements. Although a few key competitors control the majority of the industry, there are still chances for smaller businesses to gain market share by creating cutting-edge goods and technology."

CURRENT DRIVERS IN THE MARKET

Increasing Incidence of cancer and other Chronic Diseases

The IHC market is expanding significantly as a result of the increasing prevalence of cancer and other chronic disorders. The growing need for personalized medicine is anticipated to increase demand for IHC in the upcoming years. IHC is widely utilized for the diagnosis and treatment of cancer and other disorders.

Advancements in Technology

The market is expanding as a result of the creation of new IHC platforms and technologies including digital pathology and multiplex assays. These technologies make it possible to identify and analyze proteins in tissue samples with greater accuracy and efficiency, which is crucial for deciphering disease causes and creating customized treatments.

Growing Demand for Personalized Medicine

The introduction of IHC in research and clinical settings is being driven by the rising desire for personalized therapy. IHC makes it possible for scientists and medical professionals to examine the expression of particular proteins in tissue samples and create tailored treatments based on the particular biological traits of each patient.

Expansion of Healthcare Infrastructure

The IHC market is expanding as a result of the development of healthcare infrastructure in emerging nations. Companies have the potential to grow in these areas and address the rising demand for diagnostic tests and personalized medication as a result of the rising investments in healthcare infrastructure in nations like China and India.

Increasing Investments in Research and Development

The pharmaceutical and biotechnology industries' rising R&D expenditures are propelling the IHC market's expansion. The need for IHC in research and clinical settings is being fueled by these firms' investments in the creation of novel medications and treatments that target certain proteins.

"Overall, it is anticipated that these drivers will support the immunohistochemistry (IHC) market's growth over the coming years, giving businesses the chance to extend their presence in growing regions and create new products and technologies."

THE SOLUTION TO YOUR MARKET CHALLENGES

High cost of IHC tests: Adoption of IHC tests may be hampered by their high price, particularly in environments with limited resources. This may restrict access to IHC testing and prevent the industry from expanding.

Solution: Companies may overcome this difficulty by creating more economical goods and technologies, such as kits and reagents that are designed to be inexpensive and simple to use. To improve access to IHC testing in environments with limited resources, corporations might collaborate with healthcare providers and governments.

Lack of Standardization: IHC testing is not standardized, which might cause results to vary and restrict the repeatability of study findings. This may obstruct market expansion and the advancement of novel treatments.

Solution: It is important to make efforts to provide standardized IHC testing techniques and recommendations. To create best practices for IHC testing and make sure that their products are verified and standardized across various laboratories and situations, businesses might work with academic and research institutes.

Limited Availability of Skilled Personnel: There is a dearth of qualified staff in many areas, and the interpretation of IHC data necessitates specialized knowledge and training. This may restrict access to IHC testing and impede market expansion.
Solution: To support the development of healthcare professionals' and researchers' IHC testing skills, businesses might invest in educational programs and training programs. In order to create training programs and curricula that are suited to the demands of various settings and areas, businesses might also collaborate with academic and research organizations.

Ethical and Regulatory Issues: IHC testing uses human tissue samples, which presents moral and legal concerns about patient confidentiality, informed permission, and data security. These problems may hinder market expansion and raise adoption hurdles.

Solution: Companies may solve these problems by creating moral and legal frameworks that make sure patient privacy and data security are given top priority during the development and use of IHC testing. In order to solve these challenges and guarantee that IHC testing is carried out in a responsible and ethical manner, businesses can also collaborate with healthcare providers and regulatory bodies to set standards and regulations.

"Overall, technical innovation, standardization, capacity building, and ethical and legal frameworks may all be used to solve these issues. The immunohistochemistry (IHC) market may develop further and offer significant insights into the diagnosis, treatment, and prevention of illnesses by solving these issues."

OPPORTUNITIES INSIDE THE MARKET

Increasing Adoption in Emerging Markets

Companies in the IHC market have a lot of potentials to build their presence and boost the acceptance of their goods and solutions thanks to the expanding healthcare infrastructure and rising investment in emerging economies like China, India, and Brazil.

Development of Multiplex Assays

A significant potential opportunity for the IHC industry is the creation of multiplex assays that provide the simultaneous detection and analysis of numerous proteins in a single tissue sample. Researchers and physicians may learn more about the molecular properties of a tissue sample via multiplex tests, which can result in more precise diagnoses and focused treatments.

Growing Demand for Companion Diagnostics

Considerable potential for market expansion in the IHC sector is provided by the rising need for companion diagnostics, which are tests used to identify patients who are likely to benefit from a specific medication. The development of companion diagnostics, which can assist to improve patient outcomes and lower healthcare costs, frequently uses IHC.

Expansion into New Applications

The market has a lot of room to develop as a result of IHC's expansion into new applications including drug discovery, biomarker identification, and disease profiling. With the use of these applications, we may be able to create novel treatments and advance our knowledge of illness mechanisms.

Development of Digital Pathology

The IHC market has a lot of room to grow as a result of the advent of digital pathology, which uses digital pictures of tissue samples. Remote tissue sample analysis is made possible by digital pathology, which also makes it easier for researchers and healthcare professionals to work together.

"For example, growing markets, the creation of multiplex assays, companion diagnostics, novel applications, and digital pathology are some of the areas where the immunohistochemistry (IHC) industry offers prospects for growth and innovation. Businesses who are able to take advantage of these opportunities will be successful in the upcoming years."

Get Direct Order of this Report: https://www.delvens.com/checkout/immunohistochemistry-market-trends-forecast-till-2028

Contact Us:

UNIT NO. 2126, TOWER B,
21ST FLOOR ALPHATHUM
SECTOR 90 NOIDA 201305, IN
+44-20-8638-5055
SALES@DELVENS.COM
WEBSITE: https://delvens.com/

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.

Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

This release was published on openPR.